Birchview Capital
Birchview Capital reported 79 stocks worth $173M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are KLAC (18.8%), BMY (8.1%) and LRCX (5.7%). Compared with Q2 2026, the fund opened new positions in RARE, CTNM and IRLA, added to SLDB, HALO and VIR, trimmed KLAC, BMY and LRCX and sold out of VERA, QURE and BIOA.
Latest filing: what Birchview Capital did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KLAC Kla Corp | $32.5M | 18.8% | 167K | −12K (−6%) | 6 of 8 | |
| 2 | ![]() BMY Bristol Myers Squibb Co | $14M | 8.1% | 224K | −73K (−25%) | 8 of 8 | |
| 3 | ![]() LRCX Lam Research Corp | $9.9M | 5.7% | 30K | −5,000 (−14%) | 4 of 8 | |
| 4 | ![]() BDSX Biodesix Inc | $8.6M | 4.9% | 287K | No change | 8 of 8 | |
| 5 | ![]() CORT Corcept Therapeutics Inc | $6.4M | 3.7% | 55K | −2,000 (−3%) | 8 of 8 | |
| 6 | ![]() OVV Ovintiv Inc | $6.2M | 3.6% | 108K | No change | 8 of 8 | |
| 7 | ![]() RARE Ultragenyx Pharmaceutical in | $5.6M | 3.2% | 374K | New position | 7 of 8 | |
| 8 | ![]() SLDB Solid Biosciences Inc | $5.2M | 3.0% | 716K | +50K (+7%) | 7 of 8 | |
| 9 | ![]() PTGX Protagonist Therapeutics Inc | $4.9M | 2.9% | 35K | No change | 8 of 8 | |
| 10 | ![]() PRTA Prothena Corp PLC | $3.8M | 2.2% | 449K | No change | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() VERA Vera Therapeutics Inc | $2.5M | 58K |
![]() QURE Uniqure NV | $2.3M | 51K |
![]() BIOA Bioage Labs Inc | $1.7M | 69K |
![]() GPCR Structure Therapeutics Inc | $1.3M | 24K |
![]() NVO Novo-Nordisk A S F | $1.2M | 24K |
🔒 Free account: see all 16.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Birchview Capital 13F FAQ
What does Birchview Capital own?
Birchview Capital reported 79 stocks worth $173M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are KLAC (18.8%), BMY (8.1%) and LRCX (5.7%). The table above lists every position in the filing (the top 10 without an account).
What did Birchview Capital buy and sell in Q3 2026?
Compared with Q2 2026: 23 new positions, 13 added to, 20 trimmed and 16 sold out. New positions include RARE, CTNM and IRLA. It sold all of VERA, QURE and BIOA.
When will Birchview Capital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Birchview Capital's portfolio worth?
The Q3 2026 filing reports $173M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

























